Current Drug Targets

Editor-in-Chief:

Francis J. Castellino
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556
USA

Back

Become EABM
Become Reviewer



Problems and Perspectives of Abdominal Aortic Aneurysm Research free to download

Volume:19   Issue: 11
Pp: 1227-1227
Hiroki Tanaka
DOI: 10.2174/138945011911180720122330



Adipocytes and Abdominal Aortic Aneurysm: Putative Potential Role of Adipocytes in the Process of AAA Development

Volume:19   Issue: 11
Pp: 1228-1232
Hirona Kugo, Tatsuya Moriyama and Nobuhiro Zaima*
DOI: 10.2174/1389450119666180115164103




Osteoclastogenesis in Abdominal Aortic Aneurysms: A New Therapeutic Target

Volume:19   Issue: 11
Pp: 1233-1240
Alexander D. Leung and Dai Yamanouchi*
DOI: 10.2174/1389450118666170925155044




Fenofibrate and Telmisartan in the Management of Abdominal Aortic Aneurysm

Volume:19   Issue: 11
Pp: 1241-1246
Sophie E. Rowbotham, Smriti M. Krishna, Corey S. Moran and Jonathan Golledge*
DOI: 10.2174/1389450119666171227224655




Therapeutic Applications of Prostaglandins and Thromboxane A2 Inhibitors in Abdominal Aortic Aneurysms

Volume:19   Issue: 11
Pp: 1247-1255
Audrey Courtois*, Georgios Makrygiannis, Jean-Paul Cheramy-Bien, Audrey Purnelle, Bernard Pirotte, Jean Michel Dogne, Julien Hanson, Jean-Olivier Defraigne, Pierre Drion and Natzi Sakalihasan
DOI: 10.2174/1389450119666171227224314




Abdominal Aortic Aneurysm (AAA): Is There a Role for the Prevention and Therapy Using Antioxidants?

Volume:19   Issue: 11
Pp: 1256-1264
Joël Pincemail*, Jean-Olivier Defraigne, Audrey Courtois, Adelin Albert, Jean-Paul Cheramy-Bien and Natzi Sakalihasan
DOI: 10.2174/1389450118666170918164601




Current Status and Perspectives on Pharmacologic Therapy for Abdominal Aortic Aneurysm open access plus

Volume:19   Issue: 11
Pp: 1265-1275
Koichi Yoshimura*, Noriyasu Morikage, Shizuka Nishino-Fujimoto, Akira Furutani, Bungo Shirasawa and Kimikazu Hamano
DOI: 10.2174/1389450119666171227223331




Role of the LDL Receptor-Related Protein 1 in Regulating Protease Activity and Signaling Pathways in the Vasculature

Volume:19   Issue: 11
Pp: 1276-1288
Dianaly T. Au, Allison L. Arai, William E. Fondrie, Selen C. Muratoglu* and Dudley K. Strickland*
DOI: 10.2174/1389450119666180511162048




Inflammatory Cells and Proteases in Abdominal Aortic Aneurysm and its Complications

Volume:19   Issue: 11
Pp: 1289-1296
Haiying Jiang, Takeshi Sasaki, Enze Jin, Masafumi Kuzuya and Xian Wu Cheng*
DOI: 10.2174/1389450119666180531103458




Optimal Time for Pharmacological Treatment of Abdominal Aortic Aneurysm

Volume:19   Issue: 11
Pp: 1297-1301
Yasunori Iida*, Shigeharu Sawa and Hideyuki Shimizu
DOI: 10.2174/1389450119666171227225008




Current Theories and Clinical Trial Evidence for Limiting Human Abdominal Aortic Aneurysm Growth

Volume:19   Issue: 11
Pp: 1302-1308
Jing Yu, Shuai Liu, Jianhua Huang and Wei Wang*
DOI: 10.2174/1389450118666171113114310




Drug Therapy for Abdominal Aortic Aneurysms Utilizing Omega-3 Unsaturated Fatty Acids and Their Derivatives

Volume:19   Issue: 11
Pp: 1309-1317
Daisuke Akagi*, Katsuyuki Hoshina, Toshiaki Watanabe and Micheal S. Conte
DOI: 10.2174/1389450118666171013101815




Pathogenic and Therapeutic Significance of Angiotensin II Type I Receptor in Abdominal Aortic Aneurysms

Volume:19   Issue: 11
Pp: 1318-1326
Baohui Xu*, Haojun Xuan, Yasunori Iida, Masaaki Miyata and Ronald L. Dalman
DOI: 10.2174/1389450119666180122155642




Hypoperfusion of the Aortic Wall Secondary to Degeneration of Adventitial Vasa Vasorum Causes Abdominal Aortic Aneurysms

Volume:19   Issue: 11
Pp: 1327-1332
Hiroki Tanaka*, Naoki Unno, Yuko Suzuki, Hideto Sano, Tatsuro Yata and Tetsumei Urano
DOI: 10.2174/1389450119666180122154409




Anesthetics Mechanisms: A Review of Putative Target Proteins at the Cellular and Molecular Level

Volume:19   Issue: 11
Pp: 1333-1343
Danuh Kim, Hyun Joo Kim and Seunghyun Ahn*
DOI: 10.2174/1389450119666180502112029




The Case for Cannabinoid CB1 Receptors as a Target for Bronchodilator Therapy for β-agonist Resistant Asthma

Volume:19   Issue: 11
Pp: 1344-1349
John C. Ashton* and Robert J. Hancox
DOI: 10.2174/1389450118666170615101220